Efficacy and safety of vinorelbine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma patients

被引：1

作者：

Barth, Claire ^{[1
]}

Naveau, Louise ^{[1
]}

Touboul, Emmanuel ^{[1
]}

Perie, Sophie ^{[2
]}

Bamogho, Edith ^{[1
]}

Haberer-Guillerm, Sophie ^{[1
]}

Schlienger, Michel ^{[1
]}

St Guily, Jean Lacau ^{[2
]}

Huguet, Florence ^{[1
]}

机构：

[1] Univ Paris 06, Tenon Hosp, HUEP, Dept Radiat Oncol, Paris, France

[2] Univ Paris 06, Tenon Hosp, HUEP, Dept Head & Neck Surg, Paris, France

来源：

ANTI-CANCER DRUGS | 2016年 / 27卷 / 04期

关键词：

vinorelbine; head and neck cancer; chemotherapy; recurrent; metastatic; PLATINUM-BASED CHEMOTHERAPY; PHASE-II TRIAL; METASTATIC HEAD; RECURRENT; CANCER; CARBOPLATIN; PACLITAXEL; CISPLATIN; CETUXIMAB; METHOTREXATE;

D O I：

10.1097/CAD.0000000000000333

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of this study was to evaluate the efficacy and tolerance of vinorelbine as a single agent in the treatment of recurrent/metastatic head and neck squamous cell carcinoma. Patients were treated with oral or intravenous vinorelbine according to the pluridisciplinary tumor board's decision. Efficacy and safety outcomes were analyzed retrospectively. Twenty-three patients were included in the study. Sixteen patients (69%) had received at least two previous lines of chemotherapy. The disease control rate was 19%. The median progression-free survival was 2.6 months and the median overall survival was 3.4 months. The rate of grade 3-4 side effects was low (13%). Only one patient discontinued treatment because of side effects. Vinorelbine seems to be a well-tolerated regimen in heavily pretreated patients. However, this regimen does not seem to be efficient enough to be recommended.

引用

页码：349 / 352

页数：4

共 50 条

[41] An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck [J].

Degardin, M ;

Oliveira, J ;

Geoffrois, L ;

Rolland, F ;

Armand, JP ;

Bastit, P ;

Chauvergne, J ;

Fargeot, P ;

van Glabbeke, M ;

Lentz, MA ;

Tresca, P ;

Boudillet, J ;

Fumoleau, P ;

Cappelaere, P .

ANNALS OF ONCOLOGY, 1998, 9 (10) :1103-1107

[42] Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study [J].

Vasiliadou, Ifigenia ;

Breik, Omar ;

Baker, Holly ;

Leslie, Isla ;

Sim, Van Ren ;

Hegarty, Gemma ;

Michaelidou, Andriana ;

Nathan, Kannon ;

Hartley, Andrew ;

Good, James ;

Sanghera, Paul ;

Fong, Charles ;

Urbano, Teresa Guerrero ;

Lei, Mary ;

Petkar, Imran ;

Ferreira, Miguel Reis ;

Nutting, Chris ;

Wong, Kee Howe ;

Newbold, Kate ;

Harrington, Kevin ;

Bhide, Shree ;

Kong, Anthony .

CANCERS, 2021, 13 (06) :1-12

[43] Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck [J].

Hong, Min Hee ;

Kim, Chang Gon ;

Koh, Yoon Woo ;

Choi, Eun Chang ;

Kim, Jinna ;

Yoon, Sun Och ;

Kim, Hye Ryun ;

Cho, Byoung Chul .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2018, 40 (01) :55-62

[44] Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck [J].

Mirabile, Aurora ;

Miceli, Rosalba ;

Calderone, Rosa Gioia ;

Locati, Laura ;

Bossi, Paolo ;

Bergamini, Cristiana ;

Granata, Roberta ;

Perrone, Federica ;

Mariani, Luigi ;

Licitra, Lisa .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (06) :1895-1902

[45] Therapeutic perspectives for recurrent or metastatic head and neck squamous cell carcinoma [J].

Gauduchon, Thibault ;

Neidhardt, Eve Marie ;

Fayette, Jerome .

CURRENT OPINION IN ONCOLOGY, 2025, 37 (03) :175-183

[46] Meta-analysis of the effects of anti-epidermal growth factor receptor on recurrent/metastatic head and neck squamous cell carcinoma [J].

Xin, Yong ;

Yan, Qiuyue ;

Yang, ChunSheng ;

Jiang, Fan ;

Guo, Wenwen ;

Huang, Qian ;

Jiang, Guan ;

Zhang, Longzhen .

MEDICINE, 2018, 97 (51)

[47] Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma [J].

Peron, Julien ;

Ceruse, Philippe ;

Lavergne, Emilie ;

Buiret, Guillaume ;

Bich-Nga Pham ;

Chabaud, Sylvie ;

Favier, Bertrand ;

Girodet, Didier ;

Zrounba, Philippe ;

Ramade, Antoine ;

Fayette, Jerome .

ANTI-CANCER DRUGS, 2012, 23 (09) :996-1001

[48] Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States [J].

Borse, Rebekah H. ;

Ramakrishnan, Karthik ;

Gandhi, Jyotika ;

Dhankhar, Praveen ;

Chirovsky, Diana .

JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) :954-965

[49] Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab [J].

Economopoulou, Panagiota ;

Kotsantis, Ioannis ;

Papaxoinis, George ;

Gavrielatou, Niki ;

Anastasiou, Maria ;

Pantazopoulos, Anastasios ;

Kavourakis, George ;

Gkolfinopoulos, Stavros ;

Panayiotides, Ioannis ;

Delides, Alexandros ;

Psyrri, Amanda .

ORAL ONCOLOGY, 2020, 111

[50] Duvelisib with Docetaxel for Patients with Anti-PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma [J].

Hanna, Glenn J. ;

Oakley, L. B. ;

Shi, R. ;

Oneill, A. ;

Shin, K. Y. ;

Scarfo, N. ;

Sehgal, K. ;

Dennis, M. J. ;

Quinn, N. ;

Jo, V. Y. ;

Wong, K. ;

Shvyrkova, A. ;

Kushnarev, V. ;

Shanthappa, B. U. ;

Tkachuk, A. ;

Kryukov, K. ;

Sarachakov, A. ;

Svekolkin, V. ;

Lennerz, J. ;

Waters, S. ;

Haddad, R. I. .

CLINICAL CANCER RESEARCH, 2025, 31 (04) :619-627

← 1 2 3 4 5 →